Evidence map›Paper›PMID 31393176›Full record

ArticleDiabetes technology & therapeutics2019

Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring.

Mary E Larkin, David M Nathan, Ionut Bebu, Heidi Krause-Steinrauf, William H Herman, John M Higgins, Margaret Tiktin, Robert M Cohen, Claire Lund, Richard M Bergenstal and 3 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes technology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01794143. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01794143 phase3completed

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study

Ran2013Enrolled7,850Registered outcomes4Posted comparisons0ConditionsComparative Effectiveness of Glycemia-lowering Medications, Type 2 DiabetesArmsDPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine), Sulfonylurea (glimepiride)
PMID 38285957PMID 37213109PMID 38194519PMID 38416773PMID 39998948PMID 38227900PMID 40388190PMID 38190625PMID 38190619PMID 38211595PMID 32139384PMID 23690531other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mary E LarkinMassachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, Massachusetts.
David M NathanMassachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, Massachusetts.
Ionut BebuThe Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute of Public Health, The George Washington University, Rockville, Maryland.
Heidi Krause-SteinraufThe Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute of Public Health, The George Washington University, Rockville, Maryland.
William H HermanInternal Medicine and Epidemiology, University of Michigan, Ann Arbor, Michigan.
John M HigginsDepartment of Systems Biology, Harvard Medical School, Boston, Massachusetts.
Margaret TiktinMultidisciplinary Research, Case Western Reserve University, Cleveland, Ohio.
Robert M CohenCincinnati VA Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Claire LundThe Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute of Public Health, The George Washington University, Rockville, Maryland.
Richard M BergenstalHealth Partners Institute, International Diabetes Center, Minneapolis, Minnesota.
Mary L JohnsonHealth Partners Institute, International Diabetes Center, Minneapolis, Minnesota.
Valerie ArendsAdvanced Research and Diagnostic Laboratory, University of Minnesota, Minneapolis, Minnesota.
GRADE Research Group

Funding

Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) StudyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Heidi Krause-Steinrauf, JOHN M LACHIN · 2021 to 2022
$21.0M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · 1986 to 2025
$12.6M
Yale Diabetes Research CenterP30DK045735 · YALE UNIVERSITY · 1993 to 2025
$10.2M
Pilot and Feasibility ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 to 2025
$4.9M
Post DPP Followup StudyU01DK048406 · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · 1994 to 2005
$3.0M
UAB Diabetes Research CenterP30DK079626 · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2025 to 2025
$1.3M
NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK045735NIDDK NIH HHS P30 DK079626NIDDK NIH HHS U01 DK048406NIDDK NIH HHS U01 DK098246
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Randomized Controlled Trials as TopicBlack or African AmericanBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 2Glycated HemoglobinHispanic or LatinoHumansHypoglycemic AgentsResearch DesignWhite PeopleBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsAverage glucoseContinuous glucose monitoringGlycated hemoglobinInterracial differencesType 2 diabetes

Identifiers

PMID31393176
PMCPMC7207016

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.